Results 21 to 30 of about 78,528 (234)

Host‐directed therapy to combat mycobacterial infections* [PDF]

Immunological Reviews, 2021
AbstractUpon infection, mycobacteria, such asMycobacterium tuberculosis(Mtb) and nontuberculous mycobacteria (NTM), are recognized by host innate immune cells, triggering a series of intracellular processes that promote mycobacterial killing. Mycobacteria, however, have developed multiple counter‐strategies to persist and survive inside host cells.
Kilinç, Gül, Saris, Anno, Ottenhoff, Tom H. M., Haks, Mariëlle C.   +3 more
openaire   +3 more sources

Editorial: Viral pathogenesis and host defense: understanding the missing links to combat disease [PDF]

Frontiers in Cellular and Infection Microbiology
Piyush Baindara, Piyush Baindara, Akil Akhtar   +2 more
doaj   +2 more sources

Host-directed therapies for COVID-19

Current Opinion in Pulmonary Medicine, 2021
Purpose of review Severe acute respiratory syndrome coronavirus-2-induced hyperinflammation is a major cause of death or end-organ dysfunction in COVID-19 patients. We review adjunct host-directed therapies (HDTs) for COVID-19 management.
Maeurer, M, Ramalho, R, Wang, F-S, Zumla, A   +3 more
openaire   +4 more sources

Host Immune-Metabolic Adaptations Upon Mycobacterial Infections and Associated Co-Morbidities

Frontiers in Immunology, 2021
Mycobacterial diseases are a major public health challenge. Their causative agents include, in order of impact, members of the Mycobacterium tuberculosis complex (causing tuberculosis), Mycobacterium leprae (causing leprosy), and non-tuberculous ...
Alba Llibre, Martin Dedicoat, Julie G. Burel, Caroline Demangel, Matthew K. O’Shea, Matthew K. O’Shea, Claudio Mauro   +6 more
doaj   +1 more source

Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial.

Lancet Respir Med, 2021
Wallis RS, Ginindza S, Beattie T, Arjun N, Likoti M, Edward VA, Rassool M, Ahmed K, Fielding K, Ahidjo BA, Vangu MDT, Churchyard G.   +11 more
europepmc   +2 more sources

Inflammation and tuberculosis: host‐directed therapies [PDF]

Journal of Internal Medicine, 2014
AbstractTuberculosis (TB) is an airborne infectious disease that kills almost two million individuals every year. Multidrug‐resistant (MDR) TB is caused by strains of Mycobacterium tuberculosis (M. tb) resistant to isoniazid and rifampin, the backbone of first‐line antitubercular treatment.
A, Zumla, M, Rao, S K, Parida, S, Keshavjee, G, Cassell, R, Wallis, R, Axelsson-Robertsson, M, Doherty, J, Andersson, M, Maeurer   +9 more
openaire   +2 more sources

Target Discovery for Host-Directed Antiviral Therapies: Application of Proteomics Approaches

mSystems, 2021
Current epidemics, such as AIDS or flu, and the emergence of new threatening pathogens, such as the one causing the current coronavirus disease 2019 (COVID-19) pandemic, represent major global health challenges.
Merve Cakir, Kirsten Obernier, Antoine Forget, Nevan J. Krogan   +3 more
doaj   +3 more sources

Lactate Metabolism and Signaling in Tuberculosis and Cancer: A Comparative Review

Frontiers in Cellular and Infection Microbiology, 2021
Infection with Mycobacterium tuberculosis (Mtb) leading to tuberculosis (TB) disease continues to be a major global health challenge. Critical barriers, including but not limited to the development of multi-drug resistance, lack of diagnostic assays that
Dilara Kiran, Randall J. Basaraba
doaj   +1 more source

A Review and Meta-Analysis of Influenza Interactome Studies

Frontiers in Microbiology, 2022
Annually, the influenza virus causes 500,000 deaths worldwide. Influenza-associated mortality and morbidity is especially high among the elderly, children, and patients with chronic diseases.
Sonja Courtney Jun Hui Chua, Sonja Courtney Jun Hui Chua, Sonja Courtney Jun Hui Chua, Sonja Courtney Jun Hui Chua, Jianzhou Cui, Jianzhou Cui, Jianzhou Cui, David Engelberg, David Engelberg, David Engelberg, Lina Hsiu Kim Lim, Lina Hsiu Kim Lim, Lina Hsiu Kim Lim   +12 more
doaj   +1 more source

Tuberculosis endotypes to guide stratified host-directed therapy [PDF]

Med, 2021
There is hope that host-directed therapy (HDT) for Tuberculosis (TB) can either shorten treatment duration, help cure drug resistant disease or limit the immunopathology. Many candidate HDT drugs have been proposed, however solid evidence only exists for a few select patient groups.
DiNardo, A.R., Nishiguchi, T., Grimm, S.L., Schlesinger, L.S., Graviss, E.A., Cirillo, J.D., Coarfa, C., Mandalakas, A.M., Heyckendorf, J., Kaufmann, S.H., Lange, C., Netea, M.G., van Crevel, R., van Crevel, R.   +13 more
openaire   +5 more sources